Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 20, 2013 3:56pm
188 Views
Post# 21018545

RE: RE: RE: RE: RE: A Little More Explanation

RE: RE: RE: RE: RE: A Little More Explanation

@KayakerBC, I acknowledge that RVX made that previous statement. But RVX has historically been very active at the annual ACC conferences and publishing in JACC. In terms of major cardiovascular disease conferences upcoming, there is ACC in March, ATVB in May and then AHA in November. Seems to me the ACC conference may be their last chance to excite people about SUSTAIN, since dosing for ASSURE will be done late March/early April and topline data for ASSURE will be announced sometime in the May/June timeframe. SUSTAIN topline data was announced almost 6 months ago. I don't see the logic in waiting until topline ASSURE data is available to present/publish on SUSTAIN. That would be a lost opportunity, IMO.

Bullboard Posts